Prevention and management of gastrointestinal side effects in patients with systemic sclerosis-interstitial lung disease receiving anti-fibrotic therapy: a modified Delphi consensus study
This study provided a detailed list of expert-based recommendations to guide everyday clinical practice of SSc-ILD, though prospective validation is needed to confirm their effectiveness in preventing and managing GI side effects.
Authors
- Carlotta Galeone (ORCID: https://orcid.org/0000-0003-1934-5167)
- Cristina Ogliari
- Nicoletta Del Papa (ORCID: https://orcid.org/0000-0003-1549-8852)
- Paolo Mariani
- Paola Cipriani
Institutions
- University of L'Aquila (IT)
- Istituto Clinico Sant'Ambrogio (IT)
- Istituto Ortopedico Gaetano Pini (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.55563/clinexprheumatol/rlzpfe
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00